Editas Medicine, INC Form 4 insider transactions

EVP and Chief Scientific Officer of Editas Medicine, Linda Burkly, reports the acquisition of stock options.

Erick Lucera, EVP and CFO of Editas Medicine, sold 4,109 shares of common stock on March 4, 2025, to cover tax obligations arising from vesting restricted stock units.

Editas Medicine CEO Gilmore O'Neill sold 16,632 shares of common stock on March 4, 2025, to cover tax withholding obligations related to vesting restricted stock units.

EVP and Chief Scientific Officer of Editas Medicine, Linda Burkly, sold 2,891 shares of common stock on March 4, 2025, to cover tax obligations resulting from vesting restricted stock units.

Editas Medicine CEO, Gilmore O'Neill, sold 1,618 shares of common stock to cover tax obligations related to vesting restricted stock units.

An Editas Medicine executive, Baisong Mei, sold 541 shares of common stock to cover tax obligations related to vesting restricted stock units.

Baisong Mei, EVP, CHIEF MEDICAL OFFICER of Editas Medicine, Inc., sold 518 shares of common stock on September 4, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Editas Medicine CEO Gilmore O'Neill sold 1,555 shares of common stock on September 4, 2024, to cover tax withholding obligations related to vesting restricted stock units.

EVP and Chief Scientific Officer of Editas Medicine, Linda Burkly, sold 11,886 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Baisong Mei, EVP, CHIEF MEDICAL OFFICER of Editas Medicine, Inc., sold 6,619 shares of common stock on July 19, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Editas Medicine CEO Gilmore O'Neill sold 12,191 shares of common stock on June 4, 2024, at a price of $5.4956 per share to cover tax withholding obligations related to vesting restricted stock units.

Baisong Mei, EVP, CHIEF MEDICAL OFFICER of Editas Medicine, sold 511 shares of common stock on June 4, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Director David Scadden acquired 25,000 stock options in Editas Medicine, Inc. on May 30, 2024.

Director Jessica Hopfield acquired 25,000 stock options in Editas Medicine, Inc. on May 30, 2024.

Director Meeta Chatterjee of Editas Medicine, Inc. reports the acquisition of stock options on May 30, 2024.

Director Andrew Hirsch reports the acquisition of stock options in Editas Medicine, Inc.

Director Emma Reeve acquired 25,000 stock options in Editas Medicine, Inc. on May 30, 2024.

Director Elliott M. Levy reports the acquisition of stock options in Editas Medicine, Inc.

Bernadette Connaughton, a director at Editas Medicine, acquired stock options for 25,000 shares on May 30, 2024.

Akshay Vaishnaw, a director at Editas Medicine, Inc., was granted stock options to purchase 25,000 shares of common stock.

EVP and CFO of Editas Medicine, Erick Lucera, sold shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Director Jessica Hopfield increased her holdings in Editas Medicine, Inc. (EDIT) by purchasing 45,000 shares of common stock at an average price of $5.6415 on May 13, 2024.

EVP and CFO Erick Lucera acquired shares and stock options in Editas Medicine, Inc. on March 2, 2024, according to a Form 4 filing.

EVP and Chief Scientific Officer of Editas Medicine, Linda Burkly, reports the acquisition of common stock and stock options, increasing her beneficial ownership in the company.

Editas Medicine CEO Gilmore O'Neill reports acquisition and disposal of company stock, including vesting of restricted stock units and option grants.

Baisong Mei, SVP, Chief Medical Officer of Editas Medicine, reports acquisition and disposal of common stock and grant of stock options.